Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effect of Sage Extract Supplementation on Cognitive Function in Middle-Aged Men and Women

NCT07757529 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2026-02-15
Last updated
2026-08-11

Condition(s) studied

Cognitive Ability, General

Investigational drug(s) / intervention(s)

SageXtraPlacebo

SageXtra: 333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule).

Placebo: 333 mg/day of methylcellulose powder in two #0 capsules.

Study summary

Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. The purpose of this study is to examine how sage supplementation affects cognitive function and reaction times in middle-aged men and women.

Eligibility

Sex
ALL
Min age
40 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * BMI 18.5-34.9 (inclusive) with a goal of being \< 30 on average * Subject agrees to maintain their existing dietary patterns throughout the study period. * Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each test day. * Subject is willing and able to comply with the study protocol. * Has given voluntary, written, informed consent to participate in the study. Exclusion Criteria: * Individuals with a personal history of a psychiatric disorder. * Individuals who are determined to have liver, renal, cardiovascular, or other metabolic disease. * Current or recent (\< 4 weeks) use of any dietary supplements (e.g., choline, lecithin, ginseng, ginkgo biloba, ashwagandha, Bacopa Monnieri, Paullina cupana, Rhodiola rosea, L-theanine, omega-3 fats, Prevagen, etc.), or currently prescribed medications (e.g., Adderall, Mydayis, Ritalin, Concerta, Mythylin, Provigil, Namenda), that may affect cognitive function (focus, concentration, memory, reaction time, energy, etc.). * Alcohol consumption (\>2 standard alcoholic drinks/day or \>10 drinks/week) or drug abuse/dependence (including regular marijuana or THC use). * Currently a smoker. * Allergy or sensitivity to study product ingredients. * Individuals who are cognitively impaired and/or who are unable to give informed consent. * Any other condition which, in the PI's opinion, may adversely affect the subject's ability to complete the study, its measurements, or pose a significant risk to the subject.

Primary outcome measure(s)

  • COMputerized Mental Performance ASsessment System (COMPASS) Test Battery — 4 weeks and 8 weeks
    COMPASS consists of seven components including; 1) Immediate and Delayed Word Recall, 2) Delayed Word Recognition, 3) Delayed Picture Recognition, 4) Corsi Blocks Task, 5) Digit Vigilance, 6) Stroop Test and, 7) Choice Reaction Time evaluated via a computer program.

Trial sites (1)

FacilityCityRegionStatus
Exercise & Sport Nutrition Lab - Texas A&M University College Station Texas Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07757529 on ClinicalTrials.gov ↗ ← All trials in the USA